CoChat
Sign Up
Cited by 27Mesenchymal stem cell researchCancer Cells and MetastasisImmune cells in cancer

New insights in application of mesenchymal stem cells therapy in tumor microenvironment: pros and cons

Open access
Afkhami, Hamed, Mahmoudvand, Golnaz, Fakouri, Arshia, Shadab, Alireza, Mahjoor, Mohamad, Komeili Movahhed, Tahereh·2023·Frontiers in Cell and Developmental Biology
DOI 10.3389/fcell.2023.1255697PMC PMC10577325
Open this paper in CoChat — free accountOpen PDF

Abstract

Multipotent mesenchymal stem cells (MSCs) are widely accepted as a useful tool for cell-based therapy of various diseases including malignancies. The therapeutic effects of MSCs are mainly attributed to their immunomodulatory and immunosuppressive properties. Despite the promising outcomes of MSCs in cancer therapy, a growing body of evidence implies that MSCs also show tumorigenic properties in the tumor microenvironment (TME), which might lead to tumor induction and progression. Owing to the broad-spectrum applications of MSCs, this challenge needs to be tackled so that they can be safely utilized in clinical practice. Herein, we review the diverse activities of MSCs in TME and highlight the potential methods to convert their protumorigenic characteristics into onco-suppressive effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcell.2023.1255697

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mesenchymal stem cells have demonstrated the ability to mediate resistance to chemotherapy and other treatments.

    “Moreover, MSCs have demonstrated the ability to mediate resistance to chemotherapy and other treatments, thereby complicating therapeutic strategies [8, 9].”

    From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [9]

    In “Immunosuppression and tumorigenesis features of MSCs” (page unavailable), the paper reports that MSCs can have chemoprotective effects and that MSC-derived cancer-associated fibroblasts aid drug resistance. These passages support resistance to chemotherapy, but do not establish resistance to other kinds of treatment. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 146 · Cited by 27

Research works printed but not linked: 135

  1. Amara I. Pramil E. Senamaud-Beaufort C. Devillers A. Macedo R. Lescaille G. (2016). Engineered mesenchymal stem cells as vectors in a suicide gene therapy against preclinical murine models for solid tumors. J. Control. Release 239, 82– 91. 10.1016/j.jconrel.2016.08.019 27565211 · DOI
  2. Amariglio N. Hirshberg A. Scheithauer B. W. Cohen Y. Loewenthal R. Trakhtenbrot L. (2009). Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6 (2), e1000029. 10.1371/journal.pmed.1000029 19226183 PMC2642879 · DOI
  3. Antes T. J. Middleton R. C. Luther K. M. Ijichi T. Peck K. A. Liu W. J. (2018). Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display. J. Nanobiotechnology 16 (1), 61. 10.1186/s12951-018-0388-4 30165851 PMC6116387 · DOI
  4. Arena S. Salati M. Sorgentoni G. Barbisan F. Orciani M. (2018). Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer. Clin. Transl. Oncol. 20 (12), 1582– 1591. 10.1007/s12094-018-1894-4 29796998 · DOI
  5. Asari S. Itakura S. Ferreri K. Liu C. P. Kuroda Y. Kandeel F. (2009). Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol. 37 (5), 604– 615. 10.1016/j.exphem.2009.01.005 19375651 PMC2747661 · DOI
  6. Atiya H. Frisbie L. Pressimone C. Coffman L. (2020). “ Mesenchymal stem cells in the tumor microenvironment,” in Tumor microenvironment: Non-hematopoietic cells. Editor Birbrair A. (Cham: Springer International Publishing), 31– 42. 32040853
  7. Bai L. Lennon D. P. Eaton V. Maier K. Caplan A. I. Miller S. D. (2009). Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57 (11), 1192– 1203. 10.1002/glia.20841 19191336 PMC2706928 · DOI
  8. Battula V. L. Evans K. W. Hollier B. G. Shi Y. Marini F. C. Ayyanan A. (2010). Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem cells 28 (8), 1435– 1445. 10.1002/stem.467 20572012 PMC3523728 · DOI
  9. Bergfeld S. A. DeClerck Y. A. (2010). Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 29 (2), 249– 261. 10.1007/s10555-010-9222-7 20411303 · DOI
  10. Bisht J. Rawat P. Sehar U. Reddy P. H. (2023). Caregivers with cancer patients: focus on hispanics. Cancers 15 (3), 626. 10.3390/cancers15030626 36765585 PMC9913516 · DOI
  11. Bonuccelli G. Avnet S. Grisendi G. Salerno M. Granchi D. Dominici M. (2014). Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget 5 (17), 7575– 7588. 10.18632/oncotarget.2243 25277190 PMC4202145 · DOI · Paper page
  12. Brogi E. Wu T. Namiki A. Isner J. M. (1994). Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 90 (2), 649– 652. 10.1161/01.cir.90.2.649 8044933 · DOI
  13. Bui Q. T. Lee K-D. Fan Y-C. Lewis B. S. Deng L-W. Tsai Y-C. (2023). Disruption of CCL2 in mesenchymal stem cells as an anti-tumor approach against prostate cancer. Cancers 15 (2), 441. 10.3390/cancers15020441 36672395 PMC9857005 · DOI
  14. Burger J. A. Tsukada N. Burger M. Zvaifler N. J. Dell'Aquila M. Kipps T. J. (2000). Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96 (8), 2655– 2663. 10.1182/blood.v96.8.2655.h8002655_2655_2663 11023495 · DOI
  15. Cavarretta I. T. Altanerova V. Matuskova M. Kucerova L. Culig Z. Altaner C. (2010). Adipose tissue–derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol. Ther. 18 (1), 223– 231. 10.1038/mt.2009.237 19844197 PMC2839205 · DOI
  16. Chen B. Ni Y. Liu J. Zhang Y. Yan F. (2018). Bone marrow-derived mesenchymal stem cells exert diverse effects on different macrophage subsets. Stem Cells Int. 2018, 8348121. 10.1155/2018/8348121 30140291 PMC6081573 · DOI
  17. Chen J. Ji T. Wu D. Jiang S. Zhao J. Lin H. (2019). Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin α5 in hepatocellular carcinoma. Cell. Death Dis. 10 (6), 425. 10.1038/s41419-019-1622-1 31142737 PMC6541606 · DOI
  18. Cousin B. Ravet E. Poglio S. De Toni F. Bertuzzi M. Lulka H. (2009). Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PloS one 4 (7), e6278. 10.1371/journal.pone.0006278 19609435 PMC2707007 · DOI
  19. de Melo S. M. Bittencourt S. Ferrazoli E. G. da Silva C. S. da Cunha F. F. da Silva F. H. (2015). The anti-tumor effects of adipose tissue mesenchymal stem cell transduced with HSV-Tk gene on U-87-driven brain tumor. PLoS One 10 (6), e0128922. 10.1371/journal.pone.0128922 26067671 PMC4467037 · DOI
  20. Debela D. T. Muzazu S. G. Heraro K. D. Ndalama M. T. Mesele B. W. Haile D. C. (2021). New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 9, 20503121211034366. 10.1177/20503121211034366 34408877 PMC8366192 · DOI · Paper page
  21. Del Fattore A. Luciano R. Saracino R. Battafarano G. Rizzo C. Pascucci L. (2015). Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells. Expert Opin. Biol. Ther. 15 (4), 495– 504. 10.1517/14712598.2015.997706 25539575 · DOI
  22. Deng Y. Zhang Y. Ye L. Zhang T. Cheng J. Chen G. (2016). Umbilical cord-derived mesenchymal stem cells instruct monocytes towards an IL10-producing phenotype by secreting IL6 and HGF. Sci. Rep. 6 (1), 37566. 10.1038/srep37566 27917866 PMC5137158 · DOI
  23. Dias S. Choy M. Alitalo K. Rafii S. (2002). Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99 (6), 2179– 2184. 10.1182/blood.v99.6.2179 11877295 · DOI
  24. Dong L. Ding C. Zheng T. Pu Y. Liu J. Zhang W. (2019). Extracellular vesicles from human umbilical cord mesenchymal stem cells treated with siRNA against ELFN1-AS1 suppress colon adenocarcinoma proliferation and migration. Am. J. Transl. Res. 11 (11), 6989– 6999. 31814902 PMC6895508
  25. Dong M. How T. Kirkbride K. C. Gordon K. J. Lee J. D. Hempel N. (2007). The type III TGF-beta receptor suppresses breast cancer progression. J. Clin. Invest. 117 (1), 206– 217. 10.1172/JCI29293 17160136 PMC1679965 · DOI
  26. Efimenko A. Starostina E. Kalinina N. Stolzing A. (2011). Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. J. Transl. Med. 9, 10. 10.1186/1479-5876-9-10 21244679 PMC3033332 · DOI
  27. Espona-Fiedler M. Manuel-Manresa P. Benítez-García C. Fontova P. Quesada R. Soto-Cerrato V. (2023). Antimetastatic properties of prodigiosin and the BH3-mimetic obatoclax (GX15-070) in melanoma. Pharmaceutics 15 (1), 97. 10.3390/pharmaceutics15010097 PMC9862601 36678726 · DOI
  28. Fallarino F. Grohmann U. You S. McGrath B. C. Cavener D. R. Vacca C. (2006). The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176 (11), 6752– 6761. 10.4049/jimmunol.176.11.6752 16709834 · DOI
  29. Fei S. Qi X. Kedong S. Guangchun J. Jian L. Wei Q. (2012). The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model. J. Cancer Res. Clin. Oncol. 138 (2), 347– 357. 10.1007/s00432-011-1104-z 22139383 PMC11824775 · DOI
  30. François S. Usunier B. Forgue-Lafitte M-E. L’Homme B. Benderitter M. Douay L. (2018). Mesenchymal stem cell administration attenuates colon cancer progression by modulating the immune component within the colorectal tumor microenvironment. Stem Cells Transl. Med. 8 (3), 285– 300. 10.1002/sctm.18-0117 30451398 PMC6392393 · DOI
  31. Galland S. Vuille J. Martin P. Letovanec I. Caignard A. Fregni G. (2017). Tumor-derived mesenchymal stem cells use distinct mechanisms to block the activity of natural killer cell subsets. Cell. Rep. 20 (12), 2891– 2905. 10.1016/j.celrep.2017.08.089 28930684 · DOI
  32. Gao P. Ding Q. Wu Z. Jiang H. Fang Z. (2010). Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 290 (2), 157– 166. 10.1016/j.canlet.2009.08.031 19786319 · DOI
  33. Gu H. Yan C. Wan H. Wu L. Liu J. Zhu Z. (2021). Mesenchymal stem cell-derived exosomes block malignant behaviors of hepatocellular carcinoma stem cells through a lncRNA C5orf66-AS1/microRNA-127-3p/DUSP1/ERK axis. Hum. Cell. 34 (6), 1812– 1829. 10.1007/s13577-021-00599-9 34431063 · DOI
  34. Guasch G. Schober M. Pasolli H. A. Conn E. B. Polak L. Fuchs E. (2007). Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell. 12 (4), 313– 327. 10.1016/j.ccr.2007.08.020 17936557 PMC2424201 · DOI
  35. Guo Y. Zhai Y. Wu L. Wang Y. Wu P. Xiong L. (2022). Mesenchymal stem cell-derived extracellular vesicles: pleiotropic impacts on breast cancer occurrence, development, and therapy. Int. J. Mol. Sci. 23 (6), 2927. 10.3390/ijms23062927 35328347 PMC8954385 · DOI
  36. Hagenhoff A. Bruns C. J. Zhao Y. von Lüttichau I. Niess H. Spitzweg C. (2016). Harnessing mesenchymal stem cell homing as an anticancer therapy. Expert Opin. Biol. Ther. 16 (9), 1079– 1092. 10.1080/14712598.2016.1196179 27270211 · DOI
  37. Han I. Yun M. Kim E-O. Kim B. Jung M-H. Kim S-H. (2018). Retraction note: umbilical cord tissue-derived mesenchymal stem cells induce apoptosis in PC-3 prostate cancer cells through activation of JNK and downregulation of PI3K/AKT signaling. Stem Cell. Res. Ther. 9 (1), 354. 10.1186/s13287-018-1113-9 30587247 PMC6307181 · DOI
  38. Hao C. Beguinot F. Condorelli G. Trencia A. Van Meir E. G. Yong V. W. (2001). Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. 61 (3), 1162– 1170. 11221847
  39. He W. Liang B. Wang C. Li S. Zhao Y. Huang Q. (2019). MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene 38 (23), 4637– 4654. 10.1038/s41388-019-0747-0 30742067 PMC6756048 · DOI
  40. Ho I. A. Toh H. C. Ng W. H. Teo Y. L. Guo C. M. Hui K. M. (2013a). Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 31 (1), 146– 155. 10.1002/stem.1247 23034897 · DOI
  41. Ho I. A. W. Toh H. C. Ng W. H. Teo Y. L. Guo C. M. Hui K. M. (2013b). Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 31 (1), 146– 155. 10.1002/stem.1247 23034897 · DOI
  42. Houghton J. Stoicov C. Nomura S. Rogers A. B. Carlson J. Li H. (2004). Gastric cancer originating from bone marrow-derived cells. Science 306 (5701), 1568– 1571. 10.1126/science.1099513 15567866 · DOI
  43. Hsu H-S. Lin J-H. Hsu T-W. Su K. Wang C-W. Yang K-Y. (2012). Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway. Lung cancer 75 (2), 167– 177. 10.1016/j.lungcan.2011.07.001 21802163 · DOI
  44. Hu B. Zhong L. Weng Y. Peng L. Huang Y. Zhao Y. (2020). Therapeutic siRNA: state of the art. Signal Transduct. Target. Ther. 5 (1), 101. 10.1038/s41392-020-0207-x 32561705 PMC7305320 · DOI · Paper page
  45. Hu X. Zhou Y. Dong K. Sun Z. Zhao D. Wang W. (2014). Programming of the development of tumor-promoting neutrophils by mesenchymal stromal cells. Cell. Physiol. Biochem. 33 (6), 1802– 1814. 10.1159/000362959 24923759 · DOI
  46. Huang F. Yao Y. Wu J. Liu Q. Zhang J. Pu X. (2017). Curcumin inhibits gastric cancer-derived mesenchymal stem cells mediated angiogenesis by regulating NF-κB/VEGF signaling. Am. J. Transl. Res. 9 (12), 5538– 5547. 29312505 PMC5752903
  47. Hung S. C. Pochampally R. R. Chen S. C. Hsu S. C. Prockop D. J. (2007). Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 25 (9), 2363– 2370. 10.1634/stemcells.2006-0686 17540857 · DOI · Paper page
  48. Janmohammadi M. Nazemi Z. Salehi A. O. M. Seyfoori A. John J. V. Nourbakhsh M. S. (2023). Cellulose-based composite scaffolds for bone tissue engineering and localized drug delivery. Bioact. Mater. 20, 137– 163. 10.1016/j.bioactmat.2022.05.018 35663339 PMC9142858 · DOI · Paper page
  49. Jia Y. Ding X. Zhou L. Zhang L. Yang X. (2021). Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1. Oncogene 40 (2), 246– 261. 10.1038/s41388-020-01486-7 33122828 · DOI
  50. Jiang X-X. Zhang Y. Liu B. Zhang S-X. Wu Y. Yu X-D. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105 (10), 4120– 4126. 10.1182/blood-2004-02-0586 15692068 · DOI
  51. Kamerkar S. LeBleu V. S. Sugimoto H. Yang S. Ruivo C. F. Melo S. A. (2017). Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546 (7659), 498– 503. 10.1038/nature22341 28607485 PMC5538883 · DOI · Paper page
  52. Kaplan R. N. Riba R. D. Zacharoulis S. Bramley A. H. Vincent L. Costa C. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (7069), 820– 827. 10.1038/nature04186 16341007 PMC2945882 · DOI · Paper page
  53. Karnoub A. E. Dash A. B. Vo A. P. Sullivan A. Brooks M. W. Bell G. W. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (7162), 557– 563. 10.1038/nature06188 17914389 · DOI · Paper page
  54. Kim D. S. Jang I. K. Lee M. W. Ko Y. J. Lee D-H. Lee J. W. (2018a). Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ. EBioMedicine 28, 261– 273. 10.1016/j.ebiom.2018.01.002 29366627 PMC5898027 · DOI
  55. Kim E. J. Kwon K. A. Lee Y. E. Kim J. H. Kim S-H. Kim J. H. (2018b). Korean Red Ginseng extract reduces hypoxia-induced epithelial-mesenchymal transition by repressing NF-κB and ERK1/2 pathways in colon cancer. J. Ginseng Res. 42 (3), 288– 297. 10.1016/j.jgr.2017.03.008 29983610 PMC6026356 · DOI
  56. König A. Menzel T. Lynen S. Wrazel L. Rosén A. Al-Katib A. (1997). Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11 (2), 258– 265. 10.1038/sj.leu.2400556 9009090 · DOI
  57. Kucerova L. Skolekova S. Matuskova M. Bohac M. Kozovska Z. (2013). Altered features and increased chemosensitivity of human breast cancer cells mediated by adipose tissue-derived mesenchymal stromal cells. BMC cancer 13, 1– 13. 10.1186/1471-2407-13-535 24209831 PMC3829110 · DOI
  58. Lai P. Weng J. Guo L. Chen X. Du X. (2019). Novel insights into MSC-EVs therapy for immune diseases. Biomark. Res. 7 (1), 6. 10.1186/s40364-019-0156-0 30923617 PMC6423844 · DOI
  59. Larmonier N. Ghiringhelli F. Larmonier C. B. Moutet M. Fromentin A. Baulot E. (2003). Freshly isolated bone marrow cells induce death of various carcinoma cell lines. Int. J. cancer 107 (5), 747– 756. 10.1002/ijc.11463 14566824 · DOI
  60. Lathrop M. J. Sage E. K. Macura S. L. Brooks E. M. Cruz F. Bonenfant N. R. (2015). Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma. Cancer Gene Ther. 22 (1), 44– 54. 10.1038/cgt.2014.68 25525034 · DOI
  61. Lee H. J. Ko J. H. Jeong H. J. Ko A. Y. Kim M. K. Wee W. R. (2015). Mesenchymal stem/stromal cells protect against autoimmunity via CCL2-dependent recruitment of myeloid-derived suppressor cells. J. Immunol. 194 (8), 3634– 3645. 10.4049/jimmunol.1402139 25769927 · DOI
  62. Liang W. Chen X. Zhang S. Fang J. Chen M. Xu Y. (2021). Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines. Cell. Mol. Biol. Lett. 26 (1), 3– 25. 10.1186/s11658-020-00246-5 33472580 PMC7818947 · DOI
  63. Liu S. Ginestier C. Ou S. J. Clouthier S. G. Patel S. H. Monville F. (2011). Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71 (2), 614– 624. 10.1158/0008-5472.CAN-10-0538 21224357 PMC3100554 · DOI · Paper page
  64. Liu X. Hu J. Sun S. Li F. Cao W. Wang Y. U. (2015). Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro. Exp. Ther. Med. 9 (4), 1192– 1200. 10.3892/etm.2015.2286 25780408 PMC4353741 · DOI
  65. Lu L. Chen G. Yang J. Ma Z. Yang Y. Hu Y. (2019). Bone marrow mesenchymal stem cells suppress growth and promote the apoptosis of glioma U251 cells through downregulation of the PI3K/AKT signaling pathway. Biomed. Pharmacother. 112, 108625. 10.1016/j.biopha.2019.108625 30784920 · DOI
  66. Ma J. Li J. Wang Y. Chen W. Zheng P. Chen Y. (2020). WSZG inhibits BMSC-induced EMT and bone metastasis in breast cancer by regulating TGF-β1/Smads signaling. Biomed. Pharmacother. 121, 109617. 10.1016/j.biopha.2019.109617 31810139 · DOI
  67. Mahjoor M. Afkhami H. Mollaei M. Nasr A. Shahriary S. Khorrami S. J. L. S. (2021). MicroRNA-30c delivered by bone marrow-mesenchymal stem cells induced apoptosis and diminished cell invasion in U-251 glioblastoma cell line. Life Sci. 279, 119643. 10.1016/j.lfs.2021.119643 34048811 · DOI
  68. Mahjoor M. Afkhami H. Najafi M. Nasr A. Khorrami S. (2022). The role of microRNA-30c in targeting interleukin 6, as an inflammatory cytokine, in the mesenchymal stem cell: A therapeutic approach in colorectal cancer. J. Cancer Res. Clin. Oncol. 149, 1– 12. 10.1007/s00432-022-04123-w PMC11797002 35876950 · DOI
  69. Mahmoudvand G. Karimi Rouzbahani A. Razavi Z. S. Mahjoor M. Afkhami H. J. FiB. (2023). Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: new insight. New insight 11, 1158484. 10.3389/fbioe.2023.1158484 PMC10133463 37122856 · DOI
  70. Malekshah O. M. Sarkar S. Nomani A. Patel N. Javidian P. Goedken M. (2019). Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis. J. Control. Release 311-312, 273– 287. 10.1016/j.jconrel.2019.09.006 31499084 PMC6884134 · DOI
  71. McKenna M. K. Englisch A. Brenner B. Smith T. Hoyos V. Suzuki M. (2021). Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol. Ther. 29 (5), 3529– 3533. 10.1016/j.ymthe.2021.10.007 34706248 PMC8636171 · DOI
  72. McLean K. Tan L. Bolland D. E. Coffman L. G. Peterson L. F. Talpaz M. (2019). Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. Oncogene 38 (9), 1576– 1584. 10.1038/s41388-018-0523-6 30305729 PMC6374186 · DOI
  73. Meisel R. Zibert A. Laryea M. Göbel U. Däubener W. Dilloo D. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (12), 4619– 4621. 10.1182/blood-2003-11-3909 15001472 · DOI
  74. Mirshekar M. Afkhami H. Razavi S. Jazi F. M. Darban-Sarokhalil D. Ohadi E. (2023). Potential antibacterial activity and healing effect of topical administration of bone marrow and adipose mesenchymal stem cells encapsulated in collagen-fibrin hydrogel scaffold on full-thickness burn wound infection caused by Pseudomonas aeruginosa. Burns. 10.1016/j.burns.2023.01.005 38042618 · DOI · Paper page
  75. Miyazaki Y. Oda T. Mori N. Kida Y. S. (2020). Adipose-derived mesenchymal stem cells differentiate into pancreatic cancer-associated fibroblasts in vitro. FEBS Open Bio 10 (11), 2268– 2281. 10.1002/2211-5463.12976 PMC7609785 32931156 · DOI
  76. Montesinos J. Flores-Figueroa E. Castillo-Medina S. Flores-Guzmán P. Hernández-Estévez E. Fajardo-Orduña G. (2009). Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy 11 (2), 163– 176. 10.1080/14653240802582075 19152152 · DOI
  77. Moslemi M. Moradi Y. Dehghanbanadaki H. Afkhami H. Khaledi M. Sedighimehr N. (2021). The association between ATM variants and risk of breast cancer: A systematic review and meta-analysis. BMC Cancer 21 (1), 27– 12. 10.1186/s12885-020-07749-6 33402103 PMC7786920 · DOI
  78. Munoz J. L. Bliss S. A. Greco S. J. Ramkissoon S. H. Ligon K. L. Rameshwar P. (2013). Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids 2 (10), e126. 10.1038/mtna.2013.60 24084846 PMC4027430 · DOI
  79. Mushahary D. Spittler A. Kasper C. Weber V. Charwat V. (2018). Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytom. Part A 93 (1), 19– 31. 10.1002/cyto.a.23242 29072818 · DOI
  80. Naderi E. H. Skah S. Ugland H. Myklebost O. Sandnes D. L. Torgersen M. L. (2015). Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death. Mol. Cancer 14 (1), 14. 10.1186/s12943-014-0278-9 25623255 PMC4323193 · DOI
  81. Nagy B. Szilberhorn L. Győrbíró D. M. Moizs M. Bajzik G. Kerpel-Fronius A. (2023). Shall we screen lung cancer with low-dose computed tomography? Cost-effectiveness in Hungary. Value Health Regional Issues 34, 55– 64. 10.1016/j.vhri.2022.10.002 36502786 · DOI
  82. Németh K. Leelahavanichkul A. Yuen P. S. Mayer B. Parmelee A. Doi K. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15 (1), 42– 49. 10.1038/nm.1905 19098906 PMC2706487 · DOI · Paper page
  83. Nilendu P. Sarode S. C. Jahagirdar D. Tandon I. Patil S. Sarode G. S. (2018). Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cell. Oncol. (Dordr) 41 (4), 353– 367. 10.1007/s13402-018-0388-2 30027403 PMC12995248 · DOI
  84. Niu J. Yue W. Le-Le Z. Bin L. Hu X. (2017). Mesenchymal stem cells inhibit T cell activation by releasing TGF-β1 from TGF-β1/GARP complex. Oncotarget 8 (59), 99784– 99800. 10.18632/oncotarget.21549 29245940 PMC5725131 · DOI
  85. Ohkouchi S. Block G. J. Katsha A. M. Kanehira M. Ebina M. Kikuchi T. (2012). Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the warburg effect by secreting STC1. Mol. Ther. 20 (2), 417– 423. 10.1038/mt.2011.259 22146344 PMC3277221 · DOI
  86. Ohlsson L. B. Varas L. Kjellman C. Edvardsen K. Lindvall M. (2003). Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp. Mol. pathology 75 (3), 248– 255. 10.1016/j.yexmp.2003.06.001 14611816 · DOI
  87. Ong H-T. Federspiel M. J. Guo C. M. Ooi L. L. Russell S. J. Peng K-W. (2013). Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J. Hepatology 59 (5), 999– 1006. 10.1016/j.jhep.2013.07.010 PMC4324731 23867315 · DOI
  88. Otsu K. Das S. Houser S. D. Quadri S. K. Bhattacharya S. Bhattacharya J. (2009). Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. J. Am. Soc. Hematol. 113 (18), 4197– 4205. 10.1182/blood-2008-09-176198 PMC2676081 19036701 · DOI
  89. Philipp D. Suhr L. Wahlers T. Choi Y-H. Paunel-Görgülü A. (2018). Preconditioning of bone marrow-derived mesenchymal stem cells highly strengthens their potential to promote IL-6-dependent M2b polarization. Stem Cell. Res. Ther. 9 (1), 286. 10.1186/s13287-018-1039-2 30359316 PMC6202843 · DOI · Paper page
  90. Quante M. Tu S. P. Tomita H. Gonda T. Wang S. S. Takashi S. (2011). Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 19 (2), 257– 272. 10.1016/j.ccr.2011.01.020 21316604 PMC3060401 · DOI
  91. Ramdasi S. Sarang S. Viswanathan C. (2015). Potential of mesenchymal stem cell based application in cancer. Int. J. hematology-oncology stem Cell. Res. 9 (2), 95– 103. PMC4410295 25922650
  92. Ren G. Zhao X. Wang Y. Zhang X. Chen X. Xu C. (2012). CCR2-Dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell. Stem Cell. 11 (6), 812– 824. 10.1016/j.stem.2012.08.013 23168163 PMC3518598 · DOI
  93. Rivera-Cruz C. M. Shearer J. J. Figueiredo Neto M. Figueiredo M. L. (2017). The immunomodulatory effects of mesenchymal stem cell polarization within the tumor microenvironment niche. Stem Cells Int. 2017, 4015039. 10.1155/2017/4015039 29181035 PMC5664329 · DOI
  94. Roccaro A. M. Sacco A. Maiso P. Azab A. K. Tai Y-T. Reagan M. (2013). BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression. J. Clin. investigation 123 (4), 1542– 1555. 10.1172/JCI66517 PMC3613927 23454749 · DOI
  95. Safari F. Shakery T. Sayadamin N. (2021). Evaluating the effect of secretome of human amniotic mesenchymal stromal cells on apoptosis induction and epithelial-mesenchymal transition inhibition in LNCaP prostate cancer cells based on 2D and 3D cell culture models. Cell. Biochem. Funct. 39 (6), 813– 820. 10.1002/cbf.3654 34128234 · DOI
  96. Sainz B. Jr. Carron E. Vallespinós M. Machado H. L. (2016). Cancer stem cells and macrophages: implications in tumor Biology and therapeutic strategies. Mediat. Inflamm. 2016, 9012369. 10.1155/2016/9012369 PMC4769767 26980947 · DOI
  97. Sangiorgi B. Panepucci R. A. (2016). Modulation of immunoregulatory properties of mesenchymal stromal cells by toll-like receptors: potential applications on GVHD. Stem Cells Int. 2016, 9434250. 10.1155/2016/9434250 27738438 PMC5050362 · DOI
  98. Sato K. Ozaki K. Oh I. Meguro A. Hatanaka K. Nagai T. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109 (1), 228– 234. 10.1182/blood-2006-02-002246 16985180 · DOI
  99. Secchiero P. Zorzet S. Tripodo C. Corallini F. Melloni E. Caruso L. (2010). Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PloS one 5 (6), e11140. 10.1371/journal.pone.0011140 20585401 PMC2886845 · DOI
  100. Shojaei S. Hashemi S. M. Ghanbarian H. Salehi M. Mohammadi‐Yeganeh S. (2019). Effect of mesenchymal stem cells‐derived exosomes on tumor microenvironment: tumor progression versus tumor suppression. J. Cell. physiology 234 (4), 3394– 3409. 10.1002/jcp.27326 30362503 · DOI
  101. Sohrabi E. Moslemi M. Rezaie E. Nafissi N. Khaledi M. Afkhami H. (2021). The tissue expression of MCT3, MCT8, and MCT9 genes in women with breast cancer. Genes. Genomics 43 (9), 1065– 1077. 10.1007/s13258-021-01116-w 34097251 · DOI
  102. Soleymaninejadian E. Pramanik K. Samadian E. (2012). Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am. J. reproductive Immunol. 67 (1), 1– 8. 10.1111/j.1600-0897.2011.01069.x 21951555 · DOI
  103. Spaggiari G. M. Abdelrazik H. Becchetti F. Moretta L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113 (26), 6576– 6583. 10.1182/blood-2009-02-203943 19398717 · DOI
  104. Spaw M. Anant S. Thomas S. M. (2017). Stromal contributions to the carcinogenic process. Mol. Carcinog. 56 (4), 1199– 1213. 10.1002/mc.22583 27787930 PMC5354948 · DOI
  105. Stamler J. S. (1994). Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell. 78 (6), 931– 936. 10.1016/0092-8674(94)90269-0 7923362 · DOI · Paper page
  106. Svobodova E. Krulova M. Zajicova A. Pokorna K. Prochazkova J. Trosan P. (2012). The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem cells Dev. 21 (6), 901– 910. 10.1089/scd.2011.0157 21663543 PMC3315754 · DOI
  107. Takeda K. Hayakawa Y. Smyth M. J. Kayagaki N. Yamaguchi N. Kakuta S. (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7 (1), 94– 100. 10.1038/83416 11135622 · DOI
  108. Tan T. T. Lai R. C. Padmanabhan J. Sim W. K. Choo A. B. Lim S. K. (2021). Assessment of tumorigenic potential in mesenchymal-stem/stromal-cell-derived small extracellular vesicles (MSC-sEV). Pharmaceuticals 14 (4), 345. 10.3390/ph14040345 33918628 PMC8069985 · DOI
  109. Tao Z. Huang C. Wang D. Wang Q. Gao Q. Zhang H. (2023). Lactate induced mesenchymal stem cells activation promotes gastric cancer cells migration and proliferation. Exp. Cell. Res. 424, 113492. 10.1016/j.yexcr.2023.113492 36702194 · DOI
  110. Tesi R. (2019). MDSC; the most important cell you have never heard of. Trends Pharmacol. Sci. 40 (1), 4– 7. 10.1016/j.tips.2018.10.008 30527590 · DOI
  111. Trivanović D. Krstić J. Djordjević I. O. Mojsilović S. Santibanez J. F. Bugarski D. (2016). The roles of mesenchymal stromal/stem cells in tumor microenvironment associated with inflammation. Mediat. Inflamm. 2016, 7314016. 10.1155/2016/7314016 PMC5007366 27630452 · DOI
  112. Ungerer C. Quade-Lyssy P. Radeke H. H. Henschler R. Königs C. Köhl U. (2014). Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells Dev. 23 (7), 755– 766. 10.1089/scd.2013.0335 24083426 PMC3967371 · DOI
  113. Vasandan A. B. Jahnavi S. Shashank C. Prasad P. Kumar A. Prasanna S. J. (2016). Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE(2)-dependent mechanism. Sci. Rep. 6, 38308. 10.1038/srep38308 27910911 PMC5133610 · DOI
  114. Villatoro A. J. Alcoholado C. Martín-Astorga MdC. Rubio N. Blanco J. Garrido C. P. (2022). Suicide gene therapy by canine mesenchymal stem cell transduced with thymidine kinase in a u-87 glioblastoma murine model: secretory profile and antitumor activity. PLOS ONE 17 (2), e0264001. 10.1371/journal.pone.0264001 35167620 PMC8846542 · DOI
  115. von Einem J. C. Guenther C. Volk H. D. Grütz G. Hirsch D. Salat C. (2019). Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: results from the phase 1/2 TREAT‐ME‐1 trial. Int. J. cancer 145 (6), 1538– 1546. 10.1002/ijc.32230 30801698 · DOI
  116. Wang Y. He L. Du Y. Zhu P. Huang G. Luo J. (2015). The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell. Stem Cell. 16 (4), 413– 425. 10.1016/j.stem.2015.03.003 25842979 · DOI
  117. Waterman R. S. Henkle S. L. Betancourt A. M. (2012). Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One 7 (9), e45590. 10.1371/journal.pone.0045590 23029122 PMC3447765 · DOI
  118. Waterman R. S. Tomchuck S. L. Henkle S. L. Betancourt A. M. (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PloS one 5 (4), e10088. 10.1371/journal.pone.0010088 20436665 PMC2859930 · DOI · Paper page
  119. Xiang J. Tang J. Song C. Yang Z. Hirst D. G. Zheng Q. J. (2009). Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy 11 (5), 516– 526. 10.1080/14653240902960429 19562576 · DOI
  120. Xie C. Xie D. Y. Lin B. L. Zhang G. L. Wang P. P. Peng L. (2013). Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway. Br. J. Cancer 109 (5), 1198– 1205. 10.1038/bjc.2013.422 23887606 PMC3778282 · DOI
  121. Xu H. Zhao G. Zhang Y. Jiang H. Wang W. Zhao D. (2019). Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2. Stem Cell. Res. Ther. 10 (1), 1– 14. 10.1186/s13287-019-1446-z 31842978 PMC6915914 · DOI
  122. Xuan X. Tian C. Zhao M. Sun Y. Huang C. (2021). Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance. Cancer Cell. Int. 21 (1), 595. 10.1186/s12935-021-02300-4 34736460 PMC8570012 · DOI
  123. Yang L. Chang N. Liu X. Han Z. Zhu T. Li C. (2012). Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-β1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor Axis. Am. J. Pathology 181 (1), 85– 97. 10.1016/j.ajpath.2012.03.014 22609227 · DOI
  124. Yuan L. Liu Y. Qu Y. Liu L. Li H. (2019b). Exosomes derived from MicroRNA-148b-3p-overexpressing human umbilical cord mesenchymal stem cells restrain breast cancer progression. Front. Oncol. 9, 1076. 10.3389/fonc.2019.01076 31696054 PMC6817568 · DOI
  125. Yuan S. X. Wang J. Yang F. Tao Q. F. Zhang J. Wang L. L. (2016). Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology 63 (2), 499– 511. 10.1002/hep.27893 25964079 · DOI
  126. Yuan Z. Bian Y. Ma X. Tang Z. Chen N. Shen M. (2019a). LncRNA H19 knockdown in human amniotic mesenchymal stem cells suppresses angiogenesis by associating with EZH2 and activating vasohibin-1. Stem Cells Dev. 28 (12), 781– 790. 10.1089/scd.2019.0014 30938218 · DOI
  127. Yüce M. Albayrak E. (2021). Tonsil-derived mesenchymal stem cells inhibit the proliferation of hematological cancer cells through downregulation of IL-6 gene expression under hyperthermia. 37897623
  128. Zeng L. Gowda B. Ahmed M. G. Abourehab M. A. Chen Z-S. Zhang C. (2023). Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol. Cancer 22 (1), 10– 50. 10.1186/s12943-022-01708-4 36635761 PMC9835394 · DOI
  129. Zhang T. Lee Y. W. Rui Y. F. Cheng T. Y. Jiang X. H. Li G. (2013a). Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell. Res. Ther. 4 (3), 70. 10.1186/scrt221 23763837 PMC3707041 · DOI
  130. Zhang T. Lee Y. W. Rui Y. F. Cheng T. Y. Jiang X. H. Li G. (2013b). Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell. Res. Ther. 4 (3), 70– 15. 10.1186/scrt221 23763837 PMC3707041 · DOI
  131. Zhang Y-M. Liu Y-Q. Liu D. Zhang L. Qin J. Zhang Z. (2019). The effects of astragalus polysaccharide on bone marrow-derived mesenchymal stem cell proliferation and morphology induced by A549 lung cancer cells. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 25, 4110– 4121. 10.12659/MSM.914219 PMC6561146 31154455 · DOI
  132. Zhao R. Chen X. Song H. Bie Q. Zhang B. (2020). Dual role of MSC-derived exosomes in tumor development. Stem Cells Int. 2020, 8844730. 10.1155/2020/8844730 32963552 PMC7499322 · DOI
  133. Zhao X. Wu X. Qian M. Song Y. Wu D. Zhang W. (2018). Knockdown of TGF-β1 expression in human umbilical cord mesenchymal stem cells reverts their exosome-mediated EMT promoting effect on lung cancer cells. Cancer Lett. 428, 34– 44. 10.1016/j.canlet.2018.04.026 29702191 · DOI
  134. Zheng H. Zou W. Shen J. Xu L. Wang S. Fu Y-X. (2016). Opposite effects of coinjection and distant injection of mesenchymal stem cells on breast tumor cell growth. Stem cells Transl. Med. 5 (9), 1216– 1228. 10.5966/sctm.2015-0300 27352928 PMC4996440 · DOI · Paper page
  135. Zhu Q. Zhang X. Zhang L. Li W. Wu H. Yuan X. (2014). The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell. Death Dis. 5 (6), e1295. 10.1038/cddis.2014.263 24946088 PMC4611735 · DOI

Authors
Afkhami, H., Mahmoudvand, G., Fakouri, A., Shadab, A., Mahjoor, M., & Komeili Movahhed, T.
Affiliations
  • Shahed University (IR)
  • Lorestan University of Medical Sciences (IR)
  • Iran University of Medical Sciences (IR)
ORCID
Venue
Frontiers in Cell and Developmental Biology
Publisher
Frontiers Media SA
Published
2023-10-02
Volume
11
Pages
1255697-1255697
ISSN
2296-634X (ISSN-L)
DOI
10.3389/fcell.2023.1255697
PMC
PMC10577325
OpenAlex
W4387305217
Cited by
27
References
146
Citations by year
2026: 4 · 2025: 13 · 2024: 9 · 2023: 1
FWCI
1.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
mesenchymal stem cells, tumor microenvironment, cancer therapy, immunomodulation, immunosuppression, tumorigenicity, oncosuppression, cell therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review